Viatris stock barely budged on the earnings release, up less than 1% and trading around US$16. That muted move sits awkwardly beside a headline that is anything but quiet. The company delivered Q2 adjusted earnings per share of US$0.69 on revenue of about US$3.8b, and management lifted full year guidance for revenue, adjusted earnings before interest, tax, depreciation and amortisation, and adjusted earnings per share.

The market is treating this as a routine quarter. The numbers highlight a sentiment gap that investors now have to close.

Is Viatris a genuine 69% valuation discount or a stock priced this low for good reason? Compare its current P/S and implied fair value directly against peers on our valuation analysis for Viatris.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$3,756.8m vs. US$3,582.1m (up 4.9%)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): loss of US$118.8m vs. loss of US$4.6m (loss widened)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$0.10 per share vs. loss of less than US$0.01 per share (loss per share widened)
• Trailing 12 Month Revenue (Q2 2026 vs. Q2 2025): US$14,737.3m vs. US$14,115.7m (up 4.4%)

Prefer clear visuals instead of another dense earnings transcript? Get a full picture of Viatris with an easy to scan view of its valuation in the company report for Viatris.

Viatris Bull Case Hinges On Pipeline And Mix Shift

Bulls argue that Viatris can shift from a heavily generic base toward higher margin products powered by biosimilars and a late stage pipeline. Q2 gives some support to that idea, but only partially. Revenue grew in the low single digits while adjusted EBITDA and adjusted EPS moved ahead faster, which points to early operating leverage and cost discipline rather than simple volume growth.

The more direct evidence sits in the pipeline milestones. FDA approval of Gwyn Lo, acceptance of the fast acting meloxicam filing and positive Phase III data for Nefecon all support the claim that Viatris has multiple late stage assets that could change the mix over time. At the same time, the quarter still showed a widened net loss and pockets of pressure in emerging markets and select branded products. That indicates the higher margin story is not yet visible in reported profitability.

Compare how Viatris talks about its higher margin pipeline with how the street is actually pricing that risk and reward. See the consensus price target analysis for Viatris

Viatris Bears Still See Missing Profit Milestones

The bearish view is that Viatris is trapped in low margin generics, with pricing pressure, rising compliance costs and a heavy debt load keeping profits and flexibility under strain. Q2 offers some support for those concerns. Revenue moved modestly, yet the company still reported a wider net loss of US$118.8m versus a loss of US$4.6m a year ago, and basic EPS loss also widened. That undercuts the idea that mix improvement is already offsetting structural pressure.

Bears also worry that execution and manufacturing risk will chip away at guidance. Management flagged the Nashik fire and FDA inspection as drivers of a US$100m to US$150m revenue hit in the second half, which is a clear operational setback. Debt remains a watch point even after refinancings and repayments. The raised adjusted guidance helps, but on core profitability and operational reliability several key milestones are still not met.

After a wider net loss, a Nashik plant setback and a dividend not fully covered by earnings, review our independent risk analysis for Viatris which shows 1 important warning sign

Stay Ahead With Viatris Insights

If Viatris looks interesting after this quarter of higher guidance but a wider net loss, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a better entry point. Once you are invested, use the Portfolio Command Center to keep your holdings organised and focus on the most important updates instead of day to day noise. For a longer term view, tap into the Community to see what other investors are watching and how they are thinking about risks and catalysts. By surfacing potential turning points and red flags early, you can stay ahead of the market and make more confident decisions.

Seeking Alternatives Beyond Viatris?

Fresh ideas move first when momentum builds, and the best entry points can vanish once the crowd catches on. Scan these curated stock lists while it matters and get in early.

• Ride potential breakout trends in high quality companies with strong balance sheets before they are widely talked about by screening for our curated 19 high quality undiscovered gems.
• Target resilient income payers that aim to keep yields flying even when sentiment cools by reviewing a focused set of 8 dividend fortresses.
• Position ahead of possible infrastructure and energy shifts by screening a hand picked universe of 89 nuclear energy infrastructure stocks that is under the radar for now, so act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.